BioSpace News Archive

Genuv Inc. announced it will release new preclinical data at two major medical conferences in June.

Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), announced its financial results for the first quarter 2022.

CVRx, Inc. announced that the management team will present at the William Blair 42nd Annual Growth Stock Conference on Monday, June 6, 2022.

RemeGen Co., Ltd., a commercial-stage biotechnology company, announced that three abstracts for disitamab vedotin have been selected for poster discussions by the 2022 American Society of Clinical Oncology Annual Meeting that will be held from June 3 to June 7 2022 in Chicago, USA.

Key factors driving global market revenue growth are increasing government support for animal care across the globe, rapid advancements in veterinary services, and increasing awareness about animal health.

GNEM has been receiving press attention lately, for two reasons: it’s uniquely challenging to diagnose and because of the recent progress made by Beverly Hills based organization the Neuromuscular Disease Foundation (NDF) in its efforts to deliver the first effective therapy to end the disease’s progression in affected patients.

The National Pancreas Foundation (“NPF”), a nonprofit organization that provides hope for those suffering from pancreatitis and pancreatic cancer, announced today at Digestive Disease Week 2022 in San Diego, the launch of the country’s largest, most inclusive pancreatic disease patient registry powered by SeqsterOS.

The report draws readers’ attention to the key segments and sub-segments of the industry and offers details on the leading regional markets, intensely competitive scenario, leading product and application segments, technology landscape, sales & distribution networks, and key industry statistics.

UCB, today announced detailed results from two Phase 3 studies which evaluated the efficacy and safety of bimekizumab versus placebo in the treatment of adults with active psoriatic arthritis who were biologic disease-modifying anti-rheumatic drug naïve (BE OPTIMAL) and in adults who had an inadequate response or intolerance to tumor necrosis factor (TNF) inhibitors (BE COMPLETE).

Increasing use of ascorbic acid in dermatology, growing R&D activities to explore cytotoxic and anti-cancer activity of ascorbic acid, and growing popularity of cosmetic and personal care products enriched with vitamin C across the globe are some key factors driving market growth